Skip to main content
Back
Watch Compare

ACTUATE THERAPEUTICS, INC.

Data quality: 83%
ACTU
NASDAQ Manufacturing Chemicals
$1.72
▼ $0.17 (-8.99%)
Mkt Cap: 43.99 M
Price
$1.86
Mkt Cap
43.99 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -19.21 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-536.74%
Below sector avg (-54.01%)
ROIC-390.17%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio2.74
Interest Coverage-1110.88

Valuation

PE (TTM|NTM)
-1.98 | -1.71
Below sector avg (-1.49)
P/B Ratio4.02
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -2.0 -1.5
P/B 4.0 1.6
ROE % -536.7 -54.0
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

4 analysts
Buy
Current
$1.72
+933.7%
Target
$17.78
$6.00
$20.06
$25.00
Forecast
Forward P/E -1.71
Forward EPS -$1.01
Est. Revenue 3.12 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$1.01
-$1.32 – -$0.59
 3.12 M 4
FY2026 -$0.66
-$0.71 – -$0.61
 0.0 2

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.25 -$0.18 +26.5%
Q32025 -$0.28 -$0.25 +9.9%
Q22025 -$0.32 -$0.30 +4.8%
Q12025 -$0.30 -$0.32 -5.5%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -22.23 M
ROE -536.74% ROA -180.11%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -19.21 M
ROIC -390.17% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.74
Interest Coverage -1110.88 Asset Turnover N/A
Working Capital 11.07 M Tangible Book Value 10.94 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.98 Forward P/E -1.71
P/B Ratio 4.02 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 14.11 Fwd Earnings Yield N/A
FCF Yield -43.67%
Market Cap 43.99 M Enterprise Value 27.06 M
Per Share
EPS (Diluted TTM) -1.06 Revenue / Share N/A
FCF / Share -0.81 OCF / Share -0.81
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 86.41%
SBC-Adj. FCF -23.95 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue — —
Net Income -22.23 M -27.29 M
EPS (Diluted) -1.06 -3.26
Gross Profit — —
Operating Income -22.50 M -25.16 M
EBITDA — —
R&D Expenses 10.29 M 18.68 M
SG&A Expenses — —
D&A — —
Interest Expense 20,250.0 18,717.0
Income Tax 800.0 800.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 14.04 M 9.32 M
Total Liabilities 6.11 M 9.21 M
Shareholders' Equity 7.92 M 104,186.0
Total Debt — —
Cash & Equivalents 13.16 M 8.64 M
Current Assets 13.64 M 9.21 M
Current Liabilities 5.71 M 8.80 M